# Sermorelin Research: GH/IGF-1 Evidence, Half-Life, Side Effects, and the Open Questions

> Sermorelin research, read straight: the pediatric height-velocity result, the older-men 24-hour GH/IGF-1 reversal, the ~10-12 minute half-life, reported side effects, and where the adult anti-aging evidence runs out. Cited throughout.

The pediatric and aging endocrine findings, the pharmacokinetics, the cognition signal, and the limits of the adult anti-aging data — each datum logged to the study that measured it.

## Before the details

Here is the research record in plain terms. Sermorelin makes the pituitary release the body's own growth hormone, and growth hormone in turn raises IGF-1, a hormone the liver makes. In children who were short because they lacked growth hormone, daily injections sped up growth. In older men, two weeks of injections pushed their growth-hormone and IGF-1 numbers back up toward young-adult levels. The peptide clears from the blood in about ten minutes, which is why longer-acting cousins were later designed. The weakest part of the record is long-term adult "anti-aging" use, where good evidence is thin.

## How sermorelin works: the GHRH-receptor cascade

Sermorelin is the 1-29 fragment of GHRH and the shortest piece that retains full GHRH activity. It binds GHRH receptors on anterior-pituitary somatotrophs and activates the adenylate cyclase / cAMP / PKA pathway, stimulating GH gene transcription and pulsatile GH release. The signal is upstream: sermorelin tells the pituitary to act rather than supplying hormone directly, so somatostatin and IGF-1 negative feedback stay intact and the pulsatile pattern of secretion is preserved. A 2025 Nature Reviews Endocrinology review synthesizes the biology of GHRH and its analogues across health and disease, covering receptor signaling, the GH/IGF-1 axis, and the therapeutic uses of GHRH agonists and antagonists [15].

## Does sermorelin work?

In the FDA-approved pediatric indication, yes — measurably. A multicenter trial of prepubertal GH-deficient children showed once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation [1]. In healthy older men, 0.5 mg and 1 mg subcutaneously twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1, and after the high dose their GH/IGF-1 parameters no longer differed from young men's, with no change in fasting glucose [2]. Long-term adult anti-aging efficacy data, by contrast, remain limited [5].

## Effects documented in the literature

The documented effects — not the marketed "benefits" — cluster on the GH/IGF-1 axis. Pediatric: accelerated linear growth in GH-deficient children [1], and sustained growth over two years in a subset of significantly short children with normal GH given 30 mcg/kg/day [8]. Aging endocrinology: reversal of age-related declines in 24-hour GH and IGF-1 in older men [2]. Diagnostics: a single intravenous GRF(1-29)NH2 bolus separated GH-deficient from normal children — normal-stature children peaked at a mean plasma GH of 80.31 ng/ml versus 13.10 ng/ml in GH-deficient children [11]. These are endpoints measured in trials, not cosmetic outcomes; the anti-aging and body-composition marketing outpaces the evidence [5].

## Half-life and pharmacokinetics

Sermorelin's plasma half-life is short — on the order of ~10-12 minutes after intravenous administration. Despite that rapid clearance, a single dose elevates serum GH for roughly 3 hours [3]. Intravenous doses of 0.25-2 mcg/kg elicited dose-dependent GH release in healthy men, while intranasal bioavailability was only ~3-5% [3]. That brevity is the engineering problem the field set out to solve: the native peptide's short duration motivated longer-acting analogs built with a D-Ala2 substitution and with DAC (Drug Affinity Complex) albumin-binding technology. [How sermorelin compares to CJC-1295](/vs-tesamorelin) covers those modifications.

## Subcutaneous injection in the studies

Subcutaneous injection was the primary studied route. The pediatric efficacy trial dosed once daily subcutaneously at bedtime [1]; the older-men study used subcutaneous twice-daily dosing for 14 days [2]. Intravenous dosing appears in pharmacokinetic and diagnostic work [3][11], and an intranasal form was tried historically but performed poorly — a 6-month pilot in eight short children given intranasal GHRH(1-29)NH2 at 50 mcg/kg three times daily saw GH peak amplitudes decline, antibodies appear in three patients by 6 weeks, and no increase in height velocity, leading the authors to call intranasal GHRH in that form unsuitable for children [7].

## What studies report before and after sermorelin treatment

"Before and after" in this literature means measured endpoints, not cosmetic photos. Before/after in GH-deficient children: first-year height velocity rose from about 4.1 to roughly 7-8 cm/year on once-daily subcutaneous GHRH(1-29) [1]. Before/after in older men: 14 days of subcutaneous GHRH(1-29) moved 24-hour GH and IGF-1 from age-suppressed values to levels indistinguishable from young men's at the high dose [2]. In short children with normal GH, evening subcutaneous GRF(1-29)NH2 at 5 mcg/kg increased growth velocity over 6 months even though 24-hour GH profiles were unchanged [10]. The honest gap is that comparable controlled before/after data for general adult anti-aging use do not exist [5].

## Reported side effects and the limits of long-term data

Across studies, reported effects of GHRH(1-29) have generally been mild — most commonly local injection-site reactions. The randomized older-adult cognition trial reported mild adverse events [6]. The principal caveats are about what is not yet known and one mechanistic concern. Long-term tolerability data for adult anti-aging use are limited, and an Annals of Internal Medicine editorial called GH-secretagogue anti-aging use "not yet ready for prime time" [5]. Because GH and IGF-1 are mitogenic (growth-promoting at the cellular level), chronically raising them is a recognized theoretical oncologic-risk consideration for any GH-axis intervention — even one that, like sermorelin, works through the body's own feedback-regulated secretion. This page describes findings; it is not a dosing recommendation.

## Sermorelin and sleep

GHRH has documented sleep-promoting effects in research: it increased slow-wave sleep in normal men, and its sleep-endocrine effects depend on the timing of administration. The connection runs both ways — GH is secreted largely during early slow-wave sleep, which is part of the rationale behind bedtime dosing in studies [1]. A clinical study of single nightly subcutaneous GHRH(1-29) injections in healthy elderly men examined exactly whether bedtime dosing could restore nocturnal GH output in aging [14].

## Sermorelin and body fat

Direct sermorelin fat-loss trials are limited. The body-composition signal in the literature comes largely from the related stabilized GHRH analog tesamorelin, which significantly reduced visceral adipose tissue versus placebo in HIV-associated fat accumulation; pulsatile GH itself contributes to lipolysis. In the older-adult cognition trial, the daily GHRH analog (tesamorelin) reduced percent body fat by 7.4% [6]. This is GHRH-axis and drug-class evidence — not a sermorelin-specific cosmetic claim. There is no robust sermorelin weight-loss trial, and anti-aging/weight marketing outpaces the evidence [5].

## Is sermorelin effective for weight loss?

There is no robust sermorelin weight-loss trial evidence. The body-composition data in this literature are from tesamorelin's effect on visceral fat in specific clinical populations and from GH's general role in lipolysis [6] — not a demonstrated general weight-loss effect of sermorelin. Treating that drug-class signal as a sermorelin weight-loss claim is exactly the kind of single-finding extrapolation the evidence does not support [5].

## Sermorelin and testosterone

Sermorelin acts on the GH/IGF-1 axis, a separate hormonal pathway from the hypothalamic-pituitary-gonadal axis that governs testosterone. The men's-health literature frames GH secretagogues around raising IGF-1 and shifting body composition [2], not around directly altering testosterone. No testosterone-altering effect of sermorelin is established in this record.

## Does sermorelin raise IGF-1?

Yes. By stimulating GH release, sermorelin drives hepatic IGF-1 production. In older men, 14 days of subcutaneous GHRH(1-29) produced dose-related IGF-1 increases that, at the high dose, brought GH/IGF-1 levels in line with those of young men — all within the physiologic range [2]. In the older-adult cognition trial, the GHRH analog raised IGF-1 by 117%, also within the physiologic range [6].

## Does sermorelin build muscle?

There is no direct sermorelin muscle-hypertrophy trial in this literature. The mechanistic rationale is the GH/IGF-1 axis, and reviews discuss GH/IGF-1 modulation as a candidate strategy against age-related muscle loss (sarcopenia) [15] — a hypothesis-level framing, not demonstrated muscle-building in healthy adults. The honest status is "plausible mechanism, no direct evidence."

## Sermorelin and the brain

GHRH administration has measurable neuroendocrine effects. In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of a daily subcutaneous GHRH analog (tesamorelin, 1 mg/day before bedtime) had a favorable effect on cognition (P=0.03; executive function P=0.005), raised IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%, with mild adverse events [6]. A related study found GHRH altered brain GABA levels in mild cognitive impairment and healthy aging.

## Can GHRH improve cognition in older adults?

In the controlled 152-participant trial above, 20 weeks of a daily subcutaneous GHRH analog had a favorable effect on cognition, raised IGF-1 by 117%, and reduced percent body fat by 7.4%, with mild adverse events [6]. The result is for a GHRH analog (tesamorelin) and is a single controlled trial — encouraging and specific, but not by itself a settled clinical indication for sermorelin.

## Frontier research on GHRH analogs

Beyond the GH/IGF-1 axis, GHRH-receptor agonist analogs have been explored preclinically. One study described a therapeutic approach to heart failure after myocardial infarction based on targeting the GHRH receptor, improving post-infarction cardiac outcomes in the model [12]. A computational drug-repurposing screen has also flagged a sermorelin signal in glioma. These are hypothesis-generating preclinical and in-silico findings — not evidence that sermorelin treats those conditions. (Analytical chemistry has kept pace: GHRH analogs in human plasma can be confirmed by immunoaffinity purification plus LC-HRMS/MS [13], the basis for anti-doping detection.)

---

A status-console reading of the sermorelin record — every regulatory and GH/IGF-1 fact tagged with its source and its operational state, the formerly-approved-now-compounded standing reported as filed and the thin adult anti-aging evidence flagged in plain view; no clinic behind this console and nothing here dosed, dispensed, or sold.